NCT05768932

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2022-12-14Est. Completion: 2026-12-24

Enrollment target: 260 participants

Locations

Yale New Haven Hospital, New Haven, Connecticut, United States
University of Miami Health System, Coral Gables, Florida, United States
Winship Cancer Institute / Emory University, Atlanta, Georgia, United States
University of Michigan, Ann Arbor, Michigan, United States
New York Medicine-New York-Presbyterian Hospital, New York, New York, United States
Montefiore Medical Center - Montefiore Hospital, New York, New York, United States
Montefiore Medical Center, The Bronx, New York, United States
OHSU Knight Cancer Institute, Portland, Oregon, United States
Mary Crowley Cancer Research, Dallas, Texas, United States
Baylor University Medical Center, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea
Asan Medical Center, Seoul, South Korea
Korean University Anam Hospital, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Seoul National University Hospital, Seoul, South Korea

MelanomaAdvanced MelanomaMetastatic MelanomaUnresectable Melanoma

CMP-001-011 is a Phase 2/3 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monot…

Phoenix, United StatesCompleted Jul 22, 2024

Advanced Vaginal AdenocarcinomaAdvanced Vaginal Adenosquamous CarcinomaAdvanced Vaginal Squamous Cell CarcinomaCervical Adenocarcinoma

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.